Baxter Announces US FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
Baxter Announces US FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform – which includes Baxter's syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite – enables clinicians to utilize a single, integrated system across a variety of patient care settings. Offering the Novum IQ LVP in the U.S. demonstrates Baxter's commitment to continued innovation in advancing infusion therapy.
輸液療法和技術領域的創新領導者百特國際公司（紐約證券交易所代碼：BAX）今天宣佈，美國食品藥品監督管理局（FDA）510（k）批准了裝有Dose IQ安全軟件的Novum IQ大容量輸液泵（LVP）。將LVP模式添加到Novum IQ輸液平台——該平台包括Baxter的帶Dose IQ安全軟件的注射器輸液泵（SYR），由IQ企業連接套件提供支持——使臨床醫生能夠在各種患者護理環境中使用單一的集成系統。在美國提供Novum IQ LVP表明了百特致力於在推進輸液療法方面持續創新的承諾。
譯文內容由第三人軟體翻譯。